An article published in STAT describes the controversry surrounding a new drug approval.  The drug, Gocovri, manufactured by Adamas Pharmaceuticals, is the first FDA-approved long-acting medication for Parkinson's disease and carries a very high price tag.  The article quotes Dr. Gellad's tweets in response to the drug pricing and further describes other responses to Gocovri's approval.